Reading this on a mobile device? Try our optimized mobile version here:

December 5, 2012
Sign upForwardArchiveAdvertise
News for nuclear medicine and molecular imaging professionals
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at

  Top Story 
Nuclear Medicine Series
CriticalPoint is offering updated education and a way to earn ASRT
Cat A or ACPE CE
. 11 unique courses address fundamental skills while meeting the needs of Nuclear Pharmacists, Technicians and Nuclear Medicine Technologists. Register @ - limited # get FREE TRAINING using code: NUCEDU
  Clinical News & Research 
UltraSPECT's Dose-Reduction Solutions standardize protocols achieving less than 9 mSv total radiation exposure
Utilization of UltraSPECT's dose reduction software complies with Image Wisely® applying clinically proven reconstruction applications enabling the usage of all protocols with no compromise in image quality. UltraSPECT provides economical upgrade options for all NM cameras. For more information click here.

  Industry Report 
  • Fovia, Blackford Analysis offer software for imaging comparison
    Fovia and British company Blackford Analysis have entered a deal to offer compatible software development kits that facilitate quicker study comparison of images from various modalities, including PET. The companies' combined technologies may allow for faster access to automatically registered data sets, which will give radiologists more time for decision making and analysis. (free registration) (12/4) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • Invivoscribe Technologies forms personalized medicine company
    Invivoscribe Technologies has launched a personalized molecular medicine company called Genection, which will focus on fields in advancing individualized therapy, including pharmacogenomics and cancer somatic mutation testing. The company will act as a connection to Together We Cure, a global program focused on using the exchange of clinical data to develop treatments for acute myeloid leukemia. GenomeWeb Daily News (free registration) (12/4) LinkedInFacebookTwitterEmail this Story
  International Developments 
  • Nordion: AECL claims $46 million in arbitration costs
    Nordion said Atomic Energy of Canada Ltd. has reported to a tribunal that arbitration with Nordion concerning the nixed MAPLE reactor project in Ontario cost it $46 million. Nordion said it may have to cover some of AECL's costs. It is evaluating the legal and financial ramifications of AECL's cost submissions and is planning to file a response early in 2013. Reuters (12/4) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  • CMS urged to release final rule on sunshine law this month
    Medtronic and the Pew Charitable Trusts have asked CMS to issue a final rule this month governing the sunshine law, which mandates that medtech firms and other health care companies report payments made to hospitals and doctors. "Many companies have already invested significant resources in preparing to comply with the sunshine provision," representatives wrote in a letter to CMS Acting Administrator Marilyn Tavenner. (Boston) (12/3) , Reuters (11/28) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
  From SNMMI 
  • Mallinckrodt provides update on Dutch High-Flux Reactor
    Mallinckrodt, the pharmaceutical business of Covidien, has provided an update regarding the delayed return to operation for the Dutch High-Flux Reactor (HFR). Mallinckrodt expects to meet their customers' needs in coming weeks, even if the HFR shutdown extends beyond mid-December. LinkedInFacebookTwitterEmail this Story
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

The forceps of our minds are clumsy things and crush the truth a little in the course of taking hold of it."
--H.G. Wells,
British author

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Account Director:   Meryl Harold   (202) 407-7828
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.®  Legal Information